Telix Pharmaceuticals Gains FDA Priority Review for Cancer Imaging Agent

Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.

Telix Pharmaceuticals Ltd. has announced that the FDA has accepted its New Drug Application for TLX101-CDx, a brain cancer imaging agent, and granted it priority review. This development could significantly enhance the precision of glioma diagnosis and management in the U.S., addressing a critical unmet need in brain cancer imaging. Telix anticipates a commercial launch in 2025, pending regulatory approval, potentially revolutionizing the standard of care in the U.S. market.

For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.